BACKGROUND: Live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) are available for children. Local and systemic immunity induced by LAIV followed a month later by LAIV and IIV followed by LAIV were investigated with virus recovery after LAIV doses as surrogates for protection against influenza on natural exposure. METHODS: Fifteen children received IIV followed by LAIV, 13 an initial dose of LAIV, and 11 a second dose of LAIV. The studies were done during autumn 2009 and autumn 2010 with the same seasonal vaccine (A/California/07/09 [H1N1], A/Perth/16/09 [H3N2], B/Brisbane/60/08). RESULTS: Twenty-eight of 39 possible influenza viral strains were recovered after the initial dose of LAIV. When LAIV followed IIV, 21 of 45 viral strains were identified. When compared to primary LAIV infection, the decreased frequency of shedding with the IIV-LAIV schedule was significant (P = .023). With LAIV-LAIV, the fewest viral strains were recovered (3/33)--numbers significantly lower (P < .001) than shedding after initial LAIV and after IIV-LAIV (P < .001). Serum hemagglutination inhibition antibody responses were more frequent after IIV than LAIV (P = .02). In contrast, more mucosal immunoglobulin A responses were seen with LAIV. CONCLUSIONS: LAIV priming induces greater inhibition of virus recovery on LAIV challenge than IIV priming. The correlate(s) of protection are the subject of ongoing analysis. CLINICAL TRIALS REGISTRATION: NCT01246999.
BACKGROUND: Live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) are available for children. Local and systemic immunity induced by LAIV followed a month later by LAIV and IIV followed by LAIV were investigated with virus recovery after LAIV doses as surrogates for protection against influenza on natural exposure. METHODS: Fifteen children received IIV followed by LAIV, 13 an initial dose of LAIV, and 11 a second dose of LAIV. The studies were done during autumn 2009 and autumn 2010 with the same seasonal vaccine (A/California/07/09 [H1N1], A/Perth/16/09 [H3N2], B/Brisbane/60/08). RESULTS: Twenty-eight of 39 possible influenza viral strains were recovered after the initial dose of LAIV. When LAIV followed IIV, 21 of 45 viral strains were identified. When compared to primary LAIV infection, the decreased frequency of shedding with the IIV-LAIV schedule was significant (P = .023). With LAIV-LAIV, the fewest viral strains were recovered (3/33)--numbers significantly lower (P < .001) than shedding after initial LAIV and after IIV-LAIV (P < .001). Serum hemagglutination inhibition antibody responses were more frequent after IIV than LAIV (P = .02). In contrast, more mucosal immunoglobulin A responses were seen with LAIV. CONCLUSIONS: LAIV priming induces greater inhibition of virus recovery on LAIV challenge than IIV priming. The correlate(s) of protection are the subject of ongoing analysis. CLINICAL TRIALS REGISTRATION: NCT01246999.
Authors: Xiao-Song He; Tyson H Holmes; Caiqiu Zhang; Kutubuddin Mahmood; George W Kemble; David B Lewis; Cornelia L Dekker; Harry B Greenberg; Ann M Arvin Journal: J Virol Date: 2006-09-13 Impact factor: 5.103
Authors: R B Belshe; P M Mendelman; J Treanor; J King; W C Gruber; P Piedra; D I Bernstein; F G Hayden; K Kotloff; K Zangwill; D Iacuzio; M Wolff Journal: N Engl J Med Date: 1998-05-14 Impact factor: 91.245
Authors: Svetlana Shcherbik; Sheila B Sergent; William G Davis; Bo Shu; John Barnes; Irina Kiseleva; Natalie Larionova; Alexander Klimov; Tatiana Bousse Journal: J Virol Methods Date: 2013-09-18 Impact factor: 2.014
Authors: Daniel F Hoft; Elizabeth Babusis; Shewangizaw Worku; Charles T Spencer; Kathleen Lottenbach; Steven M Truscott; Getahun Abate; Isaac G Sakala; Kathryn M Edwards; C Buddy Creech; Michael A Gerber; David I Bernstein; Frances Newman; Irene Graham; Edwin L Anderson; Robert B Belshe Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Shai Ashkenazi; Andre Vertruyen; Javier Arístegui; Susanna Esposito; David Douglas McKeith; Timo Klemola; Jiri Biolek; Joachim Kühr; Tadeusz Bujnowski; Daniel Desgrandchamps; Sheau-Mei Cheng; Jonathan Skinner; William C Gruber; Bruce D Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Sinthujan Jegaskanda; Catherine Luke; Heather D Hickman; Mark Y Sangster; Wendy F Wieland-Alter; Jacqueline M McBride; Jon W Yewdell; Peter F Wright; John Treanor; Carrie M Rosenberger; Kanta Subbarao Journal: J Infect Dis Date: 2016-06-28 Impact factor: 5.226
Authors: Daniel F Hoft; Kathleen R Lottenbach; Azra Blazevic; Aldin Turan; Tamara P Blevins; Thomas P Pacatte; Yinyi Yu; Michelle C Mitchell; Stella G Hoft; Robert B Belshe Journal: Clin Vaccine Immunol Date: 2017-01-05
Authors: Gannon C K Mak; Stephen S Y Lau; Edman T K Lam; Ken H L Ng; Rickjason C W Chan Journal: Influenza Other Respir Viruses Date: 2022-06-01 Impact factor: 5.606
Authors: Jessie R Chung; Brendan Flannery; Mark G Thompson; Manjusha Gaglani; Michael L Jackson; Arnold S Monto; Mary Patricia Nowalk; H Keipp Talbot; John J Treanor; Edward A Belongia; Kempapura Murthy; Lisa A Jackson; Joshua G Petrie; Richard K Zimmerman; Marie R Griffin; Huong Q McLean; Alicia M Fry Journal: Pediatrics Date: 2016-01-05 Impact factor: 7.124
Authors: Matthew P DeBerge; Kenneth H Ely; Peter F Wright; Edward B Thorp; Richard I Enelow Journal: J Leukoc Biol Date: 2015-05-27 Impact factor: 4.962
Authors: Peter F Wright; Anne G Hoen; Natalia A Ilyushina; Eric P Brown; Margaret E Ackerman; Wendy Wieland-Alter; Ruth I Connor; Sinthujan Jegaskanda; Yael Rosenberg-Hasson; Brenda C Haynes; Catherine J Luke; Kanta Subbarao; John J Treanor Journal: Open Forum Infect Dis Date: 2016-05-23 Impact factor: 3.835
Authors: Min Z Levine; Judith M Martin; F Liaini Gross; Stacie Jefferson; Kelly Stefano Cole; Crystal Ann Archibald; Mary Patricia Nowalk; Michael Susick; Krissy Moehling; Sarah Spencer; Jessie R Chung; Brendan Flannery; Richard K Zimmerman Journal: Clin Vaccine Immunol Date: 2016-10-04
Authors: John C Victor; Kristen D C Lewis; Aldiouma Diallo; Mbayame N Niang; Bou Diarra; Ndongo Dia; Justin R Ortiz; Marc-Alain Widdowson; Jodi Feser; Rebecca Hoagland; Shannon L Emery; Kathryn E Lafond; Kathleen M Neuzil Journal: Lancet Glob Health Date: 2016-10-13 Impact factor: 26.763